Dr. Reddy’s Q1 net plunges 69% to ₹435.6 cr on lower revenue
Hyderabad-based generic drugmaker Dr. Reddy’s Laboratories’ consolidated net profit slumped 69% year-on-year (YoY) to ₹.435.6 crore in the June quarter amid lower sales of cancer drug lenalidomide and nearly ₹240 crore provision necessitated by recent quality issue around weight loss drug Semaglutide. Total revenue from operations stood at ₹8,099.8 crore (₹8,572.1 crore), showed its results…
Read More “Dr. Reddy’s Q1 net plunges 69% to ₹435.6 cr on lower revenue” »